What's Happening?
Johanna Mercier, Chief Commercial Officer at Gilead Sciences, has been recognized for her leadership in launching a groundbreaking HIV prevention medicine, Yeztugo (lenacapavir). In 2025, Mercier spearheaded the global commercial strategy for this twice-yearly
injectable, marking a significant milestone as it became the first HIV product approved simultaneously in the U.S., EU, and sub-Saharan Africa. Her efforts included forming partnerships with the Global Fund and PEPFAR to provide the therapy at no profit to Gilead for up to two million people over three years, until generic versions are available. The initiative aims to expand patient access across key therapeutic areas, with the first doses already delivered to Eswatini and Zambia.
Why It's Important?
This development is crucial as it addresses the ongoing global challenge of HIV, particularly in sub-Saharan Africa, where two-thirds of the world's HIV-positive population resides. By making Yeztugo available at no profit, Gilead Sciences is setting a precedent for pharmaceutical companies to prioritize public health over profits in critical areas. The strategy not only enhances Gilead's reputation but also potentially saves millions of lives by increasing access to effective HIV prevention. This move could influence other pharmaceutical companies to adopt similar models, thereby accelerating the availability of essential medicines in low-income regions.
What's Next?
Gilead Sciences plans to continue its efforts to expand access to Yeztugo by working with six manufacturers under royalty-free licensing agreements. These agreements aim to provide the drug to 120 low- and lower-middle-income countries, pending necessary approvals. The success of this initiative could lead to broader adoption of similar strategies for other essential medicines, potentially transforming global health policies and pharmaceutical practices.
Beyond the Headlines
The introduction of Yeztugo highlights the ethical responsibility of pharmaceutical companies in addressing global health disparities. By prioritizing access over profit, Gilead is challenging the traditional business model in the pharmaceutical industry. This approach may prompt discussions on the role of corporate social responsibility in healthcare and inspire policy changes that encourage more equitable distribution of life-saving medicines.
